Literature DB >> 8734022

Prognosis of childhood epilepsy in newly referred patients.

E Hauser1, M Freilinger, R Seidl, C Groh.   

Abstract

The aim of this study was to investigate the prognosis of childhood epilepsy and to analyze prognostic factors in addition to remission rate in a follow-up of newly referred patients. Two hundred eighty-one patients were followed for a mean period of 5.3 years. Overall, 253 patients (90%) achieved 1-year remission. The beginning of a 1-year seizure-free period was achieved in 77.9% by 1 year, in 84% by 2 years and in 88.6% by 3 years after onset of treatment. Early onset of seizures, symptomatic etiology, and neurologic handicap predicted a worse prognosis. In 44 of 253 children with complete suppression of seizures for 1 year, relapses occurred within the follow-up period. In one child with a relapse, remission could not be achieved in the 2nd year thereafter. In conclusion, our study shows a good prognosis for most children with epilepsy, especially in patients with idiopathic epilepsy and late onset of seizures and without neurologic dysfunction. Moreover, our data strongly suggest that the long-term pattern of seizure control is largely established during the first 2 years of treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8734022     DOI: 10.1177/088307389601100307

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  9 in total

1.  A population-based study of long-term outcomes of cryptogenic focal epilepsy in childhood: cryptogenic epilepsy is probably not symptomatic epilepsy.

Authors:  Elaine C Wirrell; Brandon R Grossardt; Elson L So; Katherine C Nickels
Journal:  Epilepsia       Date:  2011-02-14       Impact factor: 5.864

Review 2.  Pharmacoresistance and the role of surgery in difficult to treat epilepsy.

Authors:  Samuel Wiebe; Nathalie Jette
Journal:  Nat Rev Neurol       Date:  2012-09-11       Impact factor: 42.937

Review 3.  Identification of pharmacoresistant epilepsy.

Authors:  Anne T Berg
Journal:  Neurol Clin       Date:  2009-11       Impact factor: 3.806

4.  Long-term outcome and risk factors for uncontrolled seizures after a first seizure in children with hematological malignancies.

Authors:  Raja B Khan; E Brannon Morris; Ching-Hon Pui; Melissa M Hudson; Yinmei Zhou; Cheng Cheng; Davonna S Ledet; Scott C Howard
Journal:  J Child Neurol       Date:  2013-05-10       Impact factor: 1.987

Review 5.  Impact of early life exposure to antiepileptic drugs on neurobehavioral outcomes based on laboratory animal and clinical research.

Authors:  Kevin G Bath; Helen E Scharfman
Journal:  Epilepsy Behav       Date:  2013-01-08       Impact factor: 2.937

6.  Clinical course and seizure outcome of idiopathic childhood epilepsy: determinants of early and long-term prognosis.

Authors:  Pinelopi Dragoumi; Olga Tzetzi; Efthimia Vargiami; Evangelos Pavlou; Konstantinos Krikonis; Eleftherios Kontopoulos; Dimitrios I Zafeiriou
Journal:  BMC Neurol       Date:  2013-12-18       Impact factor: 2.474

7.  Patients with nodding syndrome in Uganda improve with symptomatic treatment: a cross-sectional study.

Authors:  Richard Idro; Hanifa Namusoke; Catherine Abbo; Byamah B Mutamba; Angelina Kakooza-Mwesige; Robert O Opoka; Abdu K Musubire; Amos D Mwaka; Bernard T Opar
Journal:  BMJ Open       Date:  2014-11-14       Impact factor: 2.692

8.  Premature mortality in active convulsive epilepsy in rural Kenya: causes and associated factors.

Authors:  Anthony K Ngugi; Christian Bottomley; Gregory Fegan; Eddie Chengo; Rachael Odhiambo; Evasius Bauni; Brian Neville; Immo Kleinschmidt; Josemir W Sander; Charles R Newton
Journal:  Neurology       Date:  2014-01-17       Impact factor: 9.910

9.  Incidence of convulsive epilepsy in a rural area in Kenya.

Authors:  Anthony K Ngugi; Christian Bottomley; J Anthony G Scott; Victor Mung'ala-Odera; Evasius Bauni; Josemir W Sander; Immo Kleinschmidt; Charles R Newton
Journal:  Epilepsia       Date:  2013-06-10       Impact factor: 6.740

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.